MRK Merck & Co. Inc.

Merck Foundation Grant Expands Project ECHO® in Vietnam and India

The Merck Foundation (Foundation) and the Extension for Community Healthcare Outcomes (ECHO) Institute™ at the University of New Mexico Health Sciences Center announced today that the Foundation has provided a grant of $7 million over five years to support the expansion of Project ECHO® to improve access to specialty care for complex, chronic conditions, such as: hepatitis C, HIV, tuberculosis, and non-communicable diseases, including diabetes and mental health conditions, in underserved communities in India and Vietnam.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170118005366/en/

Project ECHO® is a telementoring model that links expert specialists with primary care providers through virtual clinics (teleECHOTM clinics), where the specialists mentor and share their knowledge through case-based learning and guided practice, enabling primary care providers to develop the ability to treat patients with complex conditions within their own communities.

Given the substantial need to improve health care and build health care providers’ capacity throughout India and Vietnam, this project has four central goals:

  • Further develop ECHO superhubs in India to provide training and technical assistance for ECHO projects throughout Asia;
  • Develop and expand ECHO hubs (specialty teams at academic medical centers or other care centers) across India and Vietnam in targeted communities;
  • Work with hubs in India and Vietnam to develop and implement training programs for community health workers to further improve the quality and availability of treatment and care; and
  • Document the impact of the ECHO model™ on improving access to specialty care for patients in rural and underserved areas in India and Vietnam.

“At Merck, we value and support our partners who are experimenting with new health care models and technologies aimed at solving complex health problems,” said Dr. Julie L. Gerberding, chief patient officer, Merck and chief executive officer, Merck Foundation. “Project ECHO® will help to make a meaningful impact on patients living with chronic conditions in India and Vietnam by empowering local providers with the specialized medical knowledge they need.”

“We are incredibly grateful for this generous donation from the Merck Foundation,” said Dr. Sanjeev Arora, creator and director of Project ECHO®. “Strengthening the skills and capabilities of primary care providers in rural or remote settings helps to ensure patients receive the right care at the right place and the right time.”

As part of the initiative, a community health worker program will be developed to further expand access to appropriate care in rural communities. The community health workers will join the more than 3,000 doctors, nurses and community health workers currently enrolled in Project ECHO’s comprehensive disease management programs. To date, more than 110 partners have launched their own ECHO hubs for more than 55 diseases and conditions in more than 20 countries.

About The Merck Foundation

The Merck Foundation is a U.S.-based, private charitable foundation. Established in 1957 by Merck, a global health care leader, the Foundation is funded entirely by the company and is Merck’s chief source of funding support to qualified non-profit charitable organizations. Since its inception, the Merck Foundation has contributed more than $870 million to support important initiatives that address societal needs and are consistent with Merck’s overall mission to help the world be well. For more information, visit www.merckgiving.com.

About the ECHO Institute

The ECHO Institute, based at the University of New Mexico Health Science Center, is a groundbreaking approach to increasing access to specialty care that started in 2003, in New Mexico. ECHO is a lifelong learning and guided practice model that revolutionizes medical education and exponentially increases workforce capacity to provide best-practice specialty care and reduce health disparities. Learn more at echo.unm.edu and on Twitter @ProjectECHO.

EN
18/01/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Merck & Co. Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Coasting as We Stalk for Buying Opportunity; Downgrading Discretionary to Underweight We had been near-term bullish on the S&P 500 (SPX) since our 4/22/25 Compass, however, we are officially downgrading our near-term outlook to neutral. The SPX, Nasdaq 100 (QQQ), and Russell 2000 (IWM) are breaking below their 50-day MAs and are also violating their multi-month uptrends, signaling a consolidation period is here. With that said, our intermediate-term outlook remains bullish (as of our 5/14/25 Co...

Merck & Co Inc: 1 director

A director at Merck & Co Inc sold 7,085 shares at 87.000USD and the significance rating of the trade was 94/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

Research Team ACF
  • Research Team ACF

ACF Thematic Oncology Lung Cancer Cough LCC 25042025

Lung Cancer Cough (LCC) is an under-served, perhaps unserved therapeutic subsegment of the Lung Cancer/Oncology market. 57-65% of early diagnosis lung cancer patients suffer from LCC, it is a highly debilitating condition. The US lung cancer therapeutics market consensus values range from ~USD 29.9bn in 2023 to ~USD 71.3bn in 2034, suggesting a compound annual growth rate (CAGR) of 8.2% over our 10 year forecast period. LCC is a prevalent symptom among lung cancer patients, and its management is...

Research Team ACF
  • Research Team ACF

Regenerative Healthcare - Stem Cells & ALS Thematic 10062024

Regenerative medicine remains an extremely exciting area of healthcare with vast investment potential. In spite of the usual setbacks in valuation and strategy, the sub-sector has pivoted and the market remains innovative and attracts investment capital. Rather than replace entire tissues, which is a complex activity, we believe the immediate future for stem cells is more likely to be in the successful stimulation of the bodies on repair mechanisms. Within regenerative medicine we believe there ...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch